{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T05:15:45Z","timestamp":1790572545622,"version":"4.1.0"},"reference-count":40,"publisher":"MDPI AG","issue":"19","license":[{"start":{"date-parts":[[2024,9,30]],"date-time":"2024-09-30T00:00:00Z","timestamp":1727654400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Mesotheliomas are hyperplastic tumors that envelop the serosal membranes that safeguard the body\u2019s external surfaces. Although certain instances may exhibit indolent characteristics, a significant number of tumors demonstrate rapid progression and a poor prognosis. Mesotheliomas are typically categorized as benign or malignant, with malignant mesothelioma being more frequently linked to asbestos exposure. Malignant pleural mesothelioma (MPM) predominantly impacts males and often emerges in the late 50 s or beyond, characterized by a median age of early 70 s among patients exposed to asbestos lasting from 2 to 4 decades. Respiratory exposure to asbestos particles leads to the development of malignant mesothelioma, characterized by recurrent inflammation, disruption of cell division, activation of proto-oncogenes, and generation of free radicals. In pleural mesothelioma, BAP1, CDKN2A, and NF are the most often mutated genes. Accurate diagnosis and assessment usually require the use of chest computed tomography (CT) scans, magnetic resonance imaging (MRI), and positron emission tomography (PET). Radiation therapy, immunotherapy, chemotherapy, and surgery are some of the treatment options that are currently available. This systematic review provides a comprehensive analysis of the latest research, biomarkers, evaluation, and management strategies for malignant pleural mesothelioma.<\/jats:p>","DOI":"10.3390\/jcm13195837","type":"journal-article","created":{"date-parts":[[2024,9,30]],"date-time":"2024-09-30T07:19:37Z","timestamp":1727680777000},"page":"5837","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":35,"title":["Malignant Pleural Mesothelioma: A Comprehensive Review"],"prefix":"10.3390","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6783-6476","authenticated-orcid":false,"given":"Molly","family":"Jain","sequence":"first","affiliation":[{"name":"Parkview Health, Fort Wayne, IN 46845, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morgan Kay","family":"Crites","sequence":"additional","affiliation":[{"name":"Parkview Health, Fort Wayne, IN 46845, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Rich","sequence":"additional","affiliation":[{"name":"Parkview Health, Fort Wayne, IN 46845, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bharat","family":"Bajantri","sequence":"additional","affiliation":[{"name":"Parkview Health, Fort Wayne, IN 46845, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,9,30]]},"reference":[{"key":"ref_1","unstructured":"Jain, S.V., and Wallen, J.M. (2024, July 17). Malignant Mesothelioma. [Updated 2023 Jul 4], StatPearls [Internet], Available online: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK519530\/."},{"key":"ref_2","unstructured":"Myers, D.J., and Babiker, H.M. (2024, July 17). Benign Mesothelioma. [Updated 2023 May 3], StatPearls [Internet], Available online: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK531485\/."},{"key":"ref_3","first-page":"e20210129","article-title":"Malignant pleural mesothelioma: An update","volume":"47","author":"Hajj","year":"2021","journal-title":"J. Bras. Pneumol."},{"key":"ref_4","unstructured":"(2024, July 15). Clinical Trial Shows Tumour-Starving Drug Improves Survival of Mesothelioma. Queen Mary University of London. Published 16 April 2023. Available online: https:\/\/www.qmul.ac.uk\/media\/news\/2023\/smd\/clinical-trial-shows-tumour-starving-drug-improves-survival-of-mesothelioma.html."},{"key":"ref_5","first-page":"70","article-title":"Mesothelioma: A review","volume":"12","author":"Mott","year":"2012","journal-title":"Ochsner J."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"537","DOI":"10.21037\/tlcr.2018.10.04","article-title":"Malignant peritoneal mesothelioma: A review","volume":"7","author":"Broeckx","year":"2018","journal-title":"Transl. Lung Cancer Res."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2510","DOI":"10.21037\/jtd-20-2761","article-title":"Epidemiology, diagnosis and treatment of the malignant pleural mesothelioma, a narrative review of literature","volume":"13","author":"Schumann","year":"2021","journal-title":"J. Thorac. Dis."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"200226","DOI":"10.1183\/16000617.0226-2020","article-title":"Update on biology and management of mesothelioma","volume":"30","author":"Asciak","year":"2021","journal-title":"Eur. Respir. Rev."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1510\/icvts.2009.213611","article-title":"Staging algorithm for diffuse malignant pleural mesothelioma","volume":"10","author":"Zielinski","year":"2010","journal-title":"Interact. Cardiovasc. Thorac. Surg."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1988","DOI":"10.1016\/j.athoracsur.2005.06.014","article-title":"Extended surgical staging for potentially resectable malignant pleural mesothelioma","volume":"80","author":"Rice","year":"2005","journal-title":"Ann. Thorac. Surg."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.21037\/tlcr.2019.11.29","article-title":"Application of immunohistochemistry in diagnosis and management of malignant mesothelioma","volume":"9","author":"Chapel","year":"2020","journal-title":"Transl. Lung Cancer Res."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"4434","DOI":"10.21037\/tcr-22-2873","article-title":"Serum diagnostic markers for malignant pleural mesothelioma: A narrative review","volume":"11","author":"Wang","year":"2022","journal-title":"Transl. Cancer Res."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Yeo, D., Castelletti, L., van Zandwijk, N., and Rasko, J.E.J. (2021). Hitting the Bull\u2019s-Eye: Mesothelin\u2019s Role as a Biomarker and Therapeutic Target for Malignant Pleural Mesothelioma. Cancers, 13.","DOI":"10.3390\/cancers13163932"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1177\/107327480601300402","article-title":"Malignant Pleural Mesothelioma: A Comprehensive Review","volume":"13","author":"Robinson","year":"2006","journal-title":"Cancer Control"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/S2213-2600(24)00119-X","article-title":"Extended pleurectomy decortication and chemotherapy versus chemotherapy alone for pleural mesothelioma (MARS 2): A phase 3 randomised controlled trial","volume":"12","author":"Lim","year":"2024","journal-title":"Lancet Respir. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"e52","DOI":"10.1016\/S2213-2600(24)00251-0","article-title":"Further insights into MARS 2","volume":"12","author":"Zhan","year":"2024","journal-title":"Lancet Respir. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"e16685","DOI":"10.1016\/j.heliyon.2023.e16685","article-title":"Comparison of video-assisted pleurectomy\/decortication surgery plus hyperthermic intrathoracic chemotherapy with VATS talc pleurodesis for the treatment of malignant pleural mesothelioma: A pilot study","volume":"9","author":"Migliore","year":"2023","journal-title":"Heliyon"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.ejso.2004.08.014","article-title":"Improved survival with VATS pleurectomy-decortication in advanced malignant mesothelioma","volume":"31","author":"Halstead","year":"2005","journal-title":"Eur. J. Surg. Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"e54","DOI":"10.1016\/S2213-2600(24)00253-4","article-title":"Further insights into MARS 2","volume":"12","author":"Migliore","year":"2024","journal-title":"Lancet Respir. Med."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"402","DOI":"10.3322\/caac.21572","article-title":"Mesothelioma: Scientific clues for prevention, diagnosis, and therapy","volume":"69","author":"Carbone","year":"2019","journal-title":"CA Cancer J. Clin."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1097\/SLA.0000000000000903","article-title":"Extrapleural pneumonectomy in the treatment of epithelioid malignant pleural mesothelioma: Novel prognostic implications of combined N1 and N2 nodal involvement based on experience in 529 patients","volume":"260","author":"Sugarbaker","year":"2014","journal-title":"Ann. Surg."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1093\/jnci\/djaa002","article-title":"The Role of Neoadjuvant Chemotherapy in Patients with Resectable Malignant Pleural Mesothelioma\u2014An Institutional and National Analysis","volume":"112","author":"Voigt","year":"2020","journal-title":"JNCI J. Natl. Cancer Inst."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/s00428-021-03031-7","article-title":"Pleural mesothelioma classification update","volume":"478","author":"Beasley","year":"2021","journal-title":"Virchows Arch."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1016\/j.jtho.2019.03.030","article-title":"The Use of Radiation Therapy for the Treatment of Malignant Pleural Mesothelioma: Expert Opinion from the National Cancer Institute Thoracic Malignancy Steering Committee, International Association for the Study of Lung Cancer, and Mesothelioma Applied Research Foundation","volume":"14","author":"Gomez","year":"2019","journal-title":"J. Thorac. Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1016\/S0360-3016(03)00287-6","article-title":"Hemithoracic radiation after extrapleural pneumonectomy for malignant pleural mesothelioma","volume":"56","author":"Yajnik","year":"2003","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"5064","DOI":"10.21037\/jtd-23-454","article-title":"Hyperthermic intrapleural chemotherapy: An update","volume":"15","author":"Campany","year":"2023","journal-title":"J. Thorac. Dis."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/S1470-2045(11)70149-8","article-title":"Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: Clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomised feasibility study","volume":"12","author":"Treasure","year":"2011","journal-title":"Lancet Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"2761","DOI":"10.1200\/JCO.2016.67.2675","article-title":"Phase II Study of Hemithoracic Intensity-Modulated Pleural Radiation Therapy (IMPRINT) as Part of Lung-Sparing Multimodality Therapy in Patients with Malignant Pleural Mesothelioma","volume":"34","author":"Rimner","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_29","unstructured":"National Comprehensive Cancer Network (2024). NCCN Clinical Practice Guidelines in Oncology: Mesothelioma, National Comprehensive Network. Available online: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/meso_pleural.pdf."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1111\/jcmm.14898","article-title":"Platinum-based combination chemotherapy triggers cancer cell death through induction of BNIP3 and ROS, but not autophagy","volume":"24","author":"Chung","year":"2020","journal-title":"J. Cell Mol. Med."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"2081","DOI":"10.1200\/JCO.2008.19.8523","article-title":"Malignant pleural mesothelioma","volume":"27","author":"Tsao","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.2174\/138945010791591395","article-title":"Vascular endothelial growth factor as an anti-angiogenic target for cancer therapy","volume":"11","author":"Niu","year":"2010","journal-title":"Curr. Drug Targets"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"2057","DOI":"10.2147\/OTT.S113598","article-title":"Spotlight on bevacizumab and its potential in the treatment of malignant pleural mesothelioma: The evidence to date","volume":"10","author":"Levin","year":"2017","journal-title":"Onco Targets Ther."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1016\/S0140-6736(15)01238-6","article-title":"Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): A randomised, controlled, open-label, phase 3 trial","volume":"387","author":"Zalcman","year":"2016","journal-title":"Lancet"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"954","DOI":"10.21037\/atm-20-5855","article-title":"Narrative review of theoretical considerations regarding HITHOC between past and future","volume":"9","author":"Molnar","year":"2021","journal-title":"Ann. Transl. Med."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Yun, K.M., and Bazhenova, L. (2024). Emerging New Targets in Systemic Therapy for Malignant Pleural Mesothelioma. Cancers, 16.","DOI":"10.3390\/cancers16071252"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S0140-6736(20)32714-8","article-title":"First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): A multicentre, randomised, open-label, phase 3 trial","volume":"397","author":"Baas","year":"2021","journal-title":"Lancet"},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Brims, F. (2021). Epidemiology and Clinical Aspects of Malignant Pleural Mesothelioma. Cancers, 13.","DOI":"10.3390\/cancers13164194"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/j.annonc.2022.01.074","article-title":"First-line nivolumab plus ipilimumab versus chemotherapy in patients with unresectable malignant pleural mesothelioma: 3-year outcomes from CheckMate 743","volume":"33","author":"Peters","year":"2022","journal-title":"Ann. Oncol."},{"key":"ref_40","unstructured":"(2024, September 25). ClinicalTrials.gov. n.d, Available online: https:\/\/clinicaltrials.gov\/search?cond=Mesothelioma%20Malignant&locStr=United%20States&country=United%20States&aggFilters=phase:3&viewType=Table&page=1."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/13\/19\/5837\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T16:07:12Z","timestamp":1760112432000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/13\/19\/5837"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,30]]},"references-count":40,"journal-issue":{"issue":"19","published-online":{"date-parts":[[2024,10]]}},"alternative-id":["jcm13195837"],"URL":"https:\/\/doi.org\/10.3390\/jcm13195837","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,30]]}}}